Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal - Yahoo Finance
Viking Therapeutics is attracting takeover interest following Vertex Pharmaceuticals' $10 billion acquisition of Crinetics Pharmaceuticals. Investors are closely monitoring Viking's obesity drug pipeline, specifically VK2735 and the new Phase 1 trial for VK3019.
Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal Bailey Pemberton Wed, July 8, 2026 at 5:12 AM EDT 4 min read VKTX +1.11% VRTX -2.24% CRNX +0.10% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in